Federated Hermes Inc. Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Federated Hermes Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 35.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,720 shares of the medical equipment provider’s stock after purchasing an additional 2,036 shares during the quarter. Federated Hermes Inc.’s holdings in Hologic were worth $557,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Stifel Financial Corp boosted its holdings in Hologic by 115.8% during the 3rd quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider’s stock valued at $1,658,000 after acquiring an additional 10,924 shares during the period. Barclays PLC increased its stake in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after buying an additional 231,578 shares during the period. Sanctuary Advisors LLC raised its holdings in Hologic by 4.2% during the 3rd quarter. Sanctuary Advisors LLC now owns 16,613 shares of the medical equipment provider’s stock valued at $1,312,000 after buying an additional 667 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Hologic during the 3rd quarter valued at $93,000. Finally, Tidal Investments LLC grew its holdings in Hologic by 60.1% in the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock worth $1,250,000 after acquiring an additional 5,764 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $56.50 on Thursday. The business has a fifty day moving average price of $61.87 and a 200-day moving average price of $71.15. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $12.68 billion, a PE ratio of 17.82, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 1-year low of $56.05 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Royal Bank of Canada reduced their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.